Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

被引：0
|
作者：
Hans-Joachim Schmoll
Julia Mann
Fabian Meinert
Benjamin Garlipp
Kersten Borchert
Arndt Vogel
Eray Goekkurt
Ulrich Kaiser
Heinz-Gert Hoeffkes
Jörn Rüssel
Stephan Kanzler
Thomas Edelmann
Helmut Forstbauer
Thomas Göhler
Carla Hannig
Bert Hildebrandt
Carsten Roll
Carsten Bokemeyer
Jörg Steighardt
Franziska Cygon
Stefan Ibach
Alexander Stein
Joseph Tintelnot
机构：
[1] University Clinic,Clinic for Internal Medicine IV—Hematology/Oncology
[2] Martin-Luther-University,Department of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg
[3] University Medical Center Hamburg-Eppendorf,Department for Surgery
[4] Oberhavel Kliniken Oranienburg,Clinic for Gastroenterology
[5] Clinic for Oncology/Hematology Klinikum Magdeburg,Clinic for Hematology/Oncology
[6] Medical University Hannover,Tumorclinic
[7] St. Bernward Krankenhaus,Medical Clinic II
[8] Klinikum Fulda,Clinic for Gastroenterology, Hematology and Medical Oncology
[9] Leopoldina Clinic Schweinfurt,Coordination Center for Clinical Trials Halle, Medical Faculty
[10] Oncological Practice Schkeuditz,undefined
[11] Oncological Practice Rheinsieg,undefined
[12] Oncological Center Dresden,undefined
[13] Oncological Practice Bottrop,undefined
[14] Klinikum Barnim,undefined
[15] Martin-Luther-University,undefined
[16] X-act Cologne Clinical Research GmbH,undefined
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：233 / 241
页数：8
相关论文
共 50 条
  • [31] FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
    Aparicio, Jorge
    Fernandez-Martos, Carlos
    Vicent, Jose M.
    Maestu, Inmaculada
    Llorca, Cristina
    Busquier, Isabel
    Campos, Jan M.
    Perez-Enguix, Daniel
    Balcells, Miquel
    [J]. CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 263 - 267
  • [32] Bevacizumab with chemotherapy for the first-line treatment of metastatic colorectal cancer: "NCI Slovakia" results
    Dolinsky, J.
    Salek, T.
    Hlavata, Z.
    Ivancova, H.
    Risnyovszka, Z.
    Mardiak, J.
    Koza, I
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [33] "CHARTA": FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer; a multivariate analysis of prognostic and predictive factors
    Meinert, F. M.
    Cygon, F.
    Stein, A.
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Steighardt, J.
    Schmoll, H. -J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 162 - 162
  • [34] Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Mizunuma, Nobuyuki
    Shinozaki, Eiji
    Ogura, Mariko
    Ozaka, Masato
    Takagi, Koichi
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [35] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
  • [36] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [37] Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial
    Tyagi, Preeta
    Grothey, Axel
    [J]. CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 261 - 264
  • [38] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Landre, Thierry
    Maillard, Emilie
    Taleb, Cherifa
    Ghebriou, Djamel
    Des Guetz, Gaetan
    Zelek, Laurent
    Aparicio, Thomas
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (08) : 1125 - 1130
  • [39] Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer
    Rocha, Jose Aurillo
    [J]. ANTI-CANCER DRUGS, 2011, 22 : S9 - S13
  • [40] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Thierry Landre
    Emilie Maillard
    Chérifa Taleb
    Djamel Ghebriou
    Gaetan Des Guetz
    Laurent Zelek
    Thomas Aparicio
    [J]. International Journal of Colorectal Disease, 2018, 33 : 1125 - 1130
12345